Clinical Trials Sponsored by Tem Innovations GmbH

Total 91 results

Tem Innovations GmbH

Unknown

ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals (ROSI-EVA)

Blood Coagulation Disorders

United States, Austria, Switzerland
Ology Bioservices
Baxter Innovations GmbH

Completed

Japanese Pediatric H5N1 Vaccine Study

Influenza

Japan
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
A.M.I. Agency for Medical Innovations GmbH

Recruiting

Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)

Fecal Incontinence

Spain, Austria, Germany
Baxter Healthcare Corporation
Baxter Innovations GmbH

Completed

Oxidized Cellulose hEmostAsis evaluatioN (OCEAN)

Intra-operative Bleeding

Czech Republic, Germany, Hungary, Poland
Urovant Sciences GmbH
Ion Channel Innovations

Terminated

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

Overactive Bladder

United States
Urovant Sciences GmbH
Ion Channel Innovations

Completed

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer (OAB)

Overactive Bladder

United States
Baxter Healthcare Corporation
Baxter Innovations GmbH

Completed

Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection

Bleeding (Oozing) in Hepatic Resection

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
Crolll Gmbh

Completed

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation (Crescendo)

Chronic Myelogenous Leukemia (CML)

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)

Myelodysplastic Syndromes

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (DSM XIII)

Multiple Myeloma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Terminated

SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment

Colorectal Carcinoma

Germany
AO Innovation Translation Center
Synthes GmbH

Active, not recruiting

Effectiveness of Hemi- Versus Total Shoulder Arthroplasty Using Implants of the "Epoca" System (Epoca H vs T)

Osteoarthritis

Germany, Austria, Sweden
Atrium Innovations
Mucos Pharma GmbH, Oberhaching, Germany

Completed

The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults

Osteoarthritis | Wobenzym

Germany
University of Göttingen
Tem International GmbH, München, Germany

Completed

Effects of an Early Prehospital Administration of Tranexamic Acid on Hyperfibrinolysis in Multiple Trauma

Mortality | Hyperfibrinolysis | Haemorrhage

Germany
Takeda
Baxalta Innovations GmbH, now part of Shire

Completed

rVWF IN PROPHYLAXIS

Von Willebrand Disease

United States, Spain, Italy, Turkey, Germany, Russian Federation, Netherlands, France, Canada
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Unknown

Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III) (NEO-RIT)

Rectal Cancer

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Terminated

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (PURO)

Urinary Bladder Cancer

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Suspended

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

Phase 1/2 Lyme Vaccine Study

Prophylaxis of Lyme Borreliosis

Germany, Austria
Urovant Sciences GmbH
Dasman Diabetes Institute; Ion Channel Innovations

Completed

Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED

Erectile Dysfunction

Kuwait
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH; Deutsche Klinik fuer Diagnostik

Completed

PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood

Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)

Germany
Otivio AS
Hannover Medical School; mediq Innovation Experts GmbH

Terminated

Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication (FlowOx)

Intermittent Claudication | Peripheral Vascular Disease | Ischemia Limb | Critical Limb Ischemia | Walking, Difficulty

Germany
Institut Pasteur
Coalition for Epidemic Preparedness Innovations; Themis Bioscience GmbH

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)

COVID-19

Belgium, France
Tel-Aviv Sourasky Medical Center
Beneo GmbH

Unknown

Investigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose or Sucrose in Infants

Malabsorption

Israel
Takeda
RTI Health Solutions; Baxalta Innovations GmbH, now part of Shire

Completed

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States
TME Pharma AG
Profil Institut für Stoffwechselforschung GmbH

Completed

NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Coalition for Epidemic Preparedness... and other collaborators

Completed

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Lassa Virus Infection

Belgium
Gesellschaft fur Medizinische Innovation - Hamatologie...

Completed

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Multiple Myeloma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...

Recruiting

National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Newly-diagnosed APL (de Novo or Therapy-related) | Relapsed APL

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...

Completed

Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma (MM_LEN_DEX_CY)

Multiple Myeloma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...

Terminated

Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines (TRACEII)

Ovarian Cancer

Germany
University of Aarhus
Innovation Fund Denmark; Arla Foods; Team Denmark

Completed

Protein Ingestion Before Training Low

Protein Metabolism
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Acquired Hemophilia A

United States, Italy, United Kingdom, Germany, Austria, Netherlands, France
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Acquired Hemophilia A

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Primary Immunodeficiency Diseases (PID)

Canada
Augusta Hospital Duesseldorf
Tel Aviv University; Storz GmbH FRG

Withdrawn

Laparoscopic Versus Open Abdominal Aortic Aneurysm (AAA) Exclusion (LapAorta)

Infra and Juxtarenal Abdominal Aortic Aneurysms
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) (AHEAD)

Hemophilia A

Czechia, Switzerland, Denmark, Canada, Australia, Austria, France, United Kingdom, Italy, Sweden, Belgium, Brazil, China, Colombia, Greece, Hungary, Norway, Poland, Portugal, Russian Federation, Slovenia, Spain
Takeda
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Completed

A Study of TAK-881 in Healthy Adults

Healthy Volunteers

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Healthy Volunteers

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)

Hemophilia A or B With Inhibitors

Croatia, North Macedonia, Ukraine
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Exposure During Pregnancy

Poland, Czechia, United States, Germany, Slovakia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 PK-guided Dosing (PROPEL)

Hemophilia A

Spain, United States, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Bulgaria, United Kingdom, Switzerland, Ukraine, Turkey, Italy, Norway, France, Austria, Romania, Sweden, Poland, Germany, Hungary, Israel

Clinical Trials Sponsored by Tem Innovations GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations